Búsqueda | Portal de Búsqueda de la BVS

1.

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.

Loriot, Y; Marabelle, A; Guégan, J P; Danlos, F X; Besse, B; Chaput, N; Massard, C; Planchard, D; Robert, C; Even, C; Khettab, M; Tselikas, L; Friboulet, L; André, F; Nafia, I; Le Loarer, F; Soria, J C; Bessede, A; Italiano, A.

Ann Oncol ; 32(11): 1381-1390, 2021 11.

Artículo en Inglés | MEDLINE | ID: mdl-34416362

2.

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.

Massard, C; Azaro, A; Soria, J-C; Lassen, U; Le Tourneau, C; Sarker, D; Smith, C; Ohnmacht, U; Oakley, G; Patel, B K R; Yuen, E S M; Benhadji, K A; Rodon, J.

Ann Oncol ; 29(9): 1911-1917, 2018 09 01.

Artículo en Inglés | MEDLINE | ID: mdl-30060061

3.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Hansen, A R; Massard, C; Ott, P A; Haas, N B; Lopez, J S; Ejadi, S; Wallmark, J M; Keam, B; Delord, J-P; Aggarwal, R; Gould, M; Yang, P; Keefe, S M; Piha-Paul, S A.

Ann Oncol ; 29(8): 1807-1813, 2018 08 01.

Artículo en Inglés | MEDLINE | ID: mdl-29992241

4.

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.

Massard, C; Mateo, J; Loriot, Y; Pezaro, C; Albiges, L; Mehra, N; Varga, A; Bianchini, D; Ryan, C J; Petrylak, D P; Attard, G; Shen, L; Fizazi, K; de Bono, J.

Ann Oncol ; 28(1): 90-95, 2017 01 01.

Artículo en Inglés | MEDLINE | ID: mdl-28039155

5.

[Management of a progressing prostate cancer: results of a national study]. / Surveillance et adaptation de la stratégie thérapeutique en cas de progression de la maladie dans le cancer de la prostate avancé : résultats d'une enquête nationale.

Rozet, F; Roupret, M; Hennequin, C; Massard, C; Blanchard, P; Le Moulec, S.

Prog Urol ; 27(6): 381-388, 2017 May.

Artículo en Francés | MEDLINE | ID: mdl-28392429

6.

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Postel-Vinay, S; Boursin, Y; Massard, C; Hollebecque, A; Ileana, E; Chiron, M; Jung, J; Lee, J S; Balogh, Z; Adam, J; Vielh, P; Angevin, E; Lacroix, L; Soria, J-C.

Ann Oncol ; 27(2): 344-52, 2016 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-26598538

7.

Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?

Laparra, A; Kfoury, M; Champiat, S; Danlos, F X; Martin-Romano, P; Simonaggio, A; Baldini, C; Vuagnat, P; Mateus, C; Voisin, A L; Albiges, L; Besse, B; Even, C; Robert, C; Laghouati, S; Massard, C; Marabelle, A; Lambotte, O; Michot, J M.

Ann Oncol ; 32(7): 936-937, 2021 07.

Artículo en Inglés | MEDLINE | ID: mdl-33865965

8.

Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients.

Aldea, M; Cerbone, L; Bayle, A; Parisi, C; Sarkozy, C; Vasseur, D; Verlingue, L; Blanc-Durand, F; Mosele, F; Sakkal, M; Ponce, S; Lavaud, P; Loriot, Y; Hollebecque, A; Massard, C; Soria, J-C; Lacroix, L; Rouleau, E; Italiano, A.

Ann Oncol ; 32(12): 1642-1645, 2021 12.

Artículo en Inglés | MEDLINE | ID: mdl-34509616

9.

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.

Lindsay, C R; Le Moulec, S; Billiot, F; Loriot, Y; Ngo-Camus, M; Vielh, P; Fizazi, K; Massard, C; Farace, F.

BMC Cancer ; 16: 168, 2016 Feb 29.

Artículo en Inglés | MEDLINE | ID: mdl-26923772

10.

Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients.

Mir, O; Watson, S; Massard, C; Le Cesne, A; Benhadji, K A; Soria, J C.

Ann Oncol ; 31(12): 1782-1784, 2020 12.

Artículo en Inglés | MEDLINE | ID: mdl-32941988

11.

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project.

Kramar, A; Negrier, S; Sylvester, R; Joniau, S; Mulders, P; Powles, T; Bex, A; Bonnetain, F; Bossi, A; Bracarda, S; Bukowski, R; Catto, J; Choueiri, T K; Crabb, S; Eisen, T; El Demery, M; Fitzpatrick, J; Flamand, V; Goebell, P J; Gravis, G; Houédé, N; Jacqmin, D; Kaplan, R; Malavaud, B; Massard, C; Melichar, B; Mourey, L; Nathan, P; Pasquier, D; Porta, C; Pouessel, D; Quinn, D; Ravaud, A; Rolland, F; Schmidinger, M; Tombal, B; Tosi, D; Vauleon, E; Volpe, A; Wolter, P; Escudier, B; Filleron, T.

Ann Oncol ; 26(12): 2392-8, 2015 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-26371288

12.

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.

Henon, C; Blay, J-Y; Massard, C; Mir, O; Bahleda, R; Dumont, S; Postel-Vinay, S; Adam, J; Soria, J-C; Le Cesne, A.

Ann Oncol ; 30(8): 1401-1403, 2019 08 01.

Artículo en Inglés | MEDLINE | ID: mdl-31114851

13.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Soria, J-C; Cortes, J; Massard, C; Armand, J-P; De Andreis, D; Ropert, S; Lopez, E; Catteau, A; James, J; Marier, J-F; Beliveau, M; Martell, R E; Baselga, J.

Ann Oncol ; 30(6): 1020, 2019 06 01.

Artículo en Inglés | MEDLINE | ID: mdl-30624604

14.

Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.

Pécuchet, N; Bigot, F; Gachet, J; Massard, C; Albiges, L; Teghom, C; Allory, Y; Méjean, A; Escudier, B; Oudard, S.

Ann Oncol ; 24(12): 2963-7, 2013 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-24190963

15.

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.

Massard, C; Kramar, A; Beyer, J; Hartmann, J T; Lorch, A; Pico, J L; Rosti, G; Droz, J P; Fizazi, K.

Ann Oncol ; 24(2): 322-328, 2013 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-23104726

16.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Loriot, Y; Bianchini, D; Ileana, E; Sandhu, S; Patrikidou, A; Pezaro, C; Albiges, L; Attard, G; Fizazi, K; De Bono, J S; Massard, C.

Ann Oncol ; 24(7): 1807-1812, 2013 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-23576708

17.

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.

Hollebecque, A; Deutsch, E; Massard, C; Gomez-Roca, C; Bahleda, R; Ribrag, V; Bourgier, C; Lazar, V; Lacroix, L; Gazzah, A; Varga, A; de Baere, T; Beier, F; Kroesser, S; Trang, K; Zenke, F T; Klevesath, M; Soria, Jean-Charles.

Invest New Drugs ; 31(6): 1530-8, 2013 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-24077982

18.

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.

Charton, E; Baldini, C; Fayet, Y; Schultz, E; Auroy, L; Vallier, E; Italiano, A; Robert, M; Coquan, E; Isambert, N; Moreau, P; Touzeau, C; Le Tourneau, C; Ghrieb, Z; Kiladjian, J-J; Delord, J-P; Gomez Roca, C; Vey, N; Barlesi, F; Lesimple, T; Penel, N; Soria, J-C; Massard, C; Besle, S.

ESMO Open ; 8(4): 101610, 2023 08.

Artículo en Inglés | MEDLINE | ID: mdl-37536254

19.

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.

Loriot, Y; Massard, C; Fizazi, K.

Ann Oncol ; 23(5): 1085-1094, 2012 May.

Artículo en Inglés | MEDLINE | ID: mdl-22267211

20.

Novel and bone-targeted agents for CRPC.

Fizazi, K; Albiges, L; Massard, C; Escudier, B; Loriot, Y.

Ann Oncol ; 23 Suppl 10: x264-7, 2012 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-22987974

Portal de Búsqueda de la BVS

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: